2019
DOI: 10.1210/js.2019-mon-570
|View full text |Cite
|
Sign up to set email alerts
|

MON-570 Clinical Utility of ThyroSeq v3 Genomic Classifier Test in Detecting Gene Fusions in Thyroid Nodules

Abstract: Background: Chromosomal rearrangements leading to gene fusions are a known molecular mechanism of thyroid cancer. ThyroSeq Genomic Classifier (GC) allows detecting most of the known fusion types preoperatively by analyzing thyroid fine-needle aspiration (FNA) samples collected from thyroid nodules, but it also facilitates discovery of novel fusion types. The goal of this study was to evaluate the prevalence and types of known and novel fusions detected in thyroid nodules during routing clinical test… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Single BRAF V600E detection with promising cost‐effectiveness studies 8 , 9 was expanded to cancer hotspot panels, to larger gene panels recently. 10 , 11 , 12 , 13 , 14 In Bethesda III or V cytology cases in particular, MD may help direct a change in management. In contrast, MD would, with rare exceptions, not cause an alteration in management in case of Bethesda IV, in the setting of current (Dutch) guidelines.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Single BRAF V600E detection with promising cost‐effectiveness studies 8 , 9 was expanded to cancer hotspot panels, to larger gene panels recently. 10 , 11 , 12 , 13 , 14 In Bethesda III or V cytology cases in particular, MD may help direct a change in management. In contrast, MD would, with rare exceptions, not cause an alteration in management in case of Bethesda IV, in the setting of current (Dutch) guidelines.…”
Section: Introductionmentioning
confidence: 99%
“…Several commercial molecular tests are available. These include for instance recently updated thyroid directed molecular diagnostics panels 15 , 16 ThyroSeq ® v3 Genomic Classifier (GC) 11 , 12 , 13 , 14 and Afirma ® Gene Sequencing Classifier (GSC). 17 , 18 Their application in clinical trials, along with cost‐effectiveness analyses, 19 has also been studied.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation